Navigation Links
New compound protects against liver cancer

Scientists have identified a new compound called CDDO-Im that protects against the development of liver cancer in laboratory animals. Experiments, led by researchers at the Johns Hopkins Bloomberg School of Public Health, show CDDO-Im to be effective at doses 100 times lower than other compounds known to prevent cancer in people. Because of its makeup, the researchers believe CDDO-Im could be particularly effective in preventing cancers with a strong link to inflammation, such as liver, colon, prostate and gastric cancers. It could also play a role in preventing diseases such as neurodegeneration, asthma and emphysema. The findings are featured in the February 15, 2006, issue of the journal Cancer Research.

CDDO-Im is a synthetic compound that belongs to a class of cancer-fighting compounds called triterpenoids under development by Dr. Michael Sporn and other study co-authors at Dartmouth Medical School. It is derived from oleanolic acid, a naturally occurring substance found in many plants. Other oleanolic derivatives are known to reduce tumor growth in animals and humans.

Researchers believe CDDO-Im works by activating Nrf2, a master switch known to direct certain enzymes to stimulate the cell's defense mechanisms and remove harmful chemicals from cells. "Activation of the Nrf2 pathway with CDDO-Im could provide protection against a number of diseases triggered by environmental agents," said Thomas Kensler, PhD, a professor with the Bloomberg School's Department of Environmental Health Sciences and lead author of the study.

In their research, Kensler and his colleagues treated laboratory rats with varying doses of CDDO-Im. Two days after treatment with CDDO-Im, the rats were given aflatoxin, a naturally occurring cancer-causing toxin. CDDO-Im treatment led to an 85 percent reduction in pre-cancerous lesions at the lowest dose of 50 micrograms per rat and a 99 percent reduction at the highest dose of 5 milligrams.

Like other compounds derived from oleanolic acid, CDDO-Im also has strong anti-inflammatory properties, which the researchers say makes it ideally suited to the prevention of certain cancers. "When cells become inflamed, they can produce reactive molecules, called free radicals, that can damage DNA and promote cancer development," explained Kensler. "CDDO-Im can also inhibit cancer formation by interfering with this inflammatory process."

Because it can stimulate the body's defense mechanisms at such low doses, Kensler believes that CDDO-Im is an excellent candidate for cancer prevention in humans. "If this compound can produce such a potent and dramatic reduction in the number of pre-cancerous growths, it should have an equally dramatic impact on the development of actual cancers. This study suggests that we may be on the right track in terms of chemoprevention. It may open the door for a new class of compounds that could prevent a number of diseases," said Kensler.


'"/>

Source:Johns Hopkins University Bloomberg School of Public Health


Related biology news :

1. Researchers discover chemical compounds that affect plant growth
2. Bacterial genome sheds light on synthesizing cancer-fighting compounds
3. Scientists discover the bodys marijuana-like compounds are crucial for stress-induced pain relief
4. Evolution of taste receptor may have shaped human sensitivity to toxic compounds
5. Novel compounds show promise as safer, more potent insecticides
6. Metal-containing compounds show promise as HIV weapon
7. Natural compound from pond scum shows potential activity against Alzheimers
8. Chemical compound inhibits tumor growth, size in new mouse study
9. Seaweed yields new compounds with pharmaceutical potential
10. Phenolic compounds may explain Mediterranean diet benefits
11. UC Berkeley researchers create a biologically-inspired artificial compound eye
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology: